Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.69 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.67 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 0.67 |
| ▸ | TNF | P01375 | 3/20 | 0.67 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.67 |
| ▸ | IL1B | P01584 | 2/20 | 0.67 |
| ▸ | BRD4 | O60885 | 1/20 | 0.67 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.52 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29505690 | 1.00 | CRBN (0.69) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL10192708 | 1.00 | CRBN (0.69) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL33677 | 1.00 | CRBN (0.69) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL1398964 | 1.00 | CRBN (0.69) | CRBNDDB1IKZF3TNFIKZF1 | |
| Hydrochloric Acid SCHEMBL27957670 | 0.99 | CRBN (0.67) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL28608567 | 0.96 | CRBN (0.64) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL19630709 | 0.93 | CRBN (0.60) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL18270887 | 0.93 | CRBN (0.60) | CRBNDDB1IKZF3TNFIKZF1 | |
| Hydrochloric Acid SCHEMBL1516330 | 0.93 | CRBN (0.62) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL19359318 | 0.88 | CRBN (0.54) | CRBNDDB1IKZF3TNFIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119371400-A | Lenalidomide amination Process for the preparation of a compound | 南京亿华药业有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20220040263-A1 | COMPANION DIAGNOSTIC FOR COMBINATION LENALIDOMIDE AND ERYTHROPOIETIN TREATMENT | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-02-10 | — | — | US | disclosed |
| US-9522899-B2 | Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof | NANJIAN CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., LTD (CN) | 2016-12-20 | — | — | US | disclosed |
| US-20150284359-A1 | Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2015-10-08 | — | — | US | disclosed |
| US-9085530-B2 | Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2015-07-21 | — | — | US | disclosed |
| EP-2438053-B1 | METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF | NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD (CN) | 2013-09-11 | — | — | EP | disclosed |
| US-20120077982-A1 | Methods for Synthesizing 3-(Substituted Dihydroisoindolinone-2-YL)-2, 6-Dioxopiperidine, and Intermediates Thereof | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2012-03-29 | — | — | US | disclosed |
| WO-2011069608-A1 | S-LENALIDOMIDE, POLYMORPHIC FORMS THEREOF AND BLEND COMPRISING S- UND R-LENALIDOMIDE | RATIOPHARM GMBH (DE) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010139266-A1 | METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220040263-A1 | COMPANION DIAGNOSTIC FOR COMBINATION LENALIDOMIDE AND ERYTHROPOIETIN TREATMENT | EPOR, IL15RA, PTPRE | CRBN 247/4885DDB1 2092/4885IKZF3 1218/4885 |
| US-20120077982-A1 | Methods for Synthesizing 3-(Substituted Dihydroisoindolinone-2-YL)-2, 6-Dioxopiperidine, and Intermediates Thereof | DHPS, QDPR, FDPS | CRBN 4078/4885DDB1 2778/4885IKZF3 1593/4885 |
| US-20150284359-A1 | Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof | DHPS, QDPR, FDPS | CRBN 4078/4885DDB1 2778/4885IKZF3 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.